Switching from Foquest 25 mg to Concerta
When switching from Foquest 25 mg to Concerta, start with Concerta 36 mg once daily in the morning, as both formulations deliver approximately the same total daily methylphenidate dose. This represents a direct 1:1 conversion based on total daily methylphenidate content.
Conversion Rationale
Foquest 25 mg delivers 25 mg of methylphenidate over approximately 12-16 hours through its multilayer-release technology. The FDA-approved Concerta dosing guidelines indicate that patients taking 10 mg methylphenidate twice or three times daily (20-30 mg total daily dose) should convert to Concerta 36 mg 1. Since Foquest 25 mg provides a similar total daily dose, Concerta 36 mg is the appropriate equivalent starting dose.
Switching Method
Perform a direct switch without tapering or overlap:
- Discontinue Foquest 25 mg
- Start Concerta 36 mg the following morning
- Administer once daily in the morning with or without food
- Swallow whole—do not crush, chew, or divide the tablet 1
The switch can be made immediately as both are methylphenidate formulations with similar mechanisms of action 1.
Dose Adjustment Strategy
After initiating Concerta 36 mg, monitor response over 1 week. If symptom control is inadequate:
- Increase by 18 mg increments at weekly intervals 1
- Maximum recommended dose: 72 mg daily for adults, 54 mg for children 6-12 years 1
- A 27 mg strength is available if dosing between 18 mg and 36 mg is needed 1
Clinical studies demonstrate that 55% of patients switching from immediate-release to sustained-release methylphenidate require higher than equivalent doses for successful conversion 2. If Concerta 36 mg provides insufficient coverage, consider:
- Increasing to Concerta 54 mg once daily, or
- Adding immediate-release methylphenidate 5-10 mg in late afternoon if evening coverage is needed 2
Monitoring Requirements
Before switching, assess for:
- Cardiac disease history (personal/family history of sudden death, arrhythmias) 1
- Blood pressure and pulse rate (establish baseline) 3
- Motor/verbal tics or Tourette's syndrome 1
After switching, monitor:
- Cardiovascular parameters: Pulse rate and blood pressure may increase with methylphenidate; regular monitoring is essential 3
- Symptom control: Use standardized rating scales (e.g., ADHD Rating Scale-IV) to assess response 4
- Adverse effects: Common side effects include decreased appetite, insomnia, headache, and mood changes 1, 5
Important Caveats
The OROS delivery system in brand-name Concerta is not therapeutically equivalent to all generic extended-release methylphenidate formulations. Non-OROS generics have demonstrated significantly reduced efficacy compared to OROS Concerta at identical doses 6. If prescribing generic methylphenidate ER, specify "OROS formulation" or "brand medically necessary" to ensure therapeutic equivalence.
Concerta provides 12-hour coverage 7, which may differ from Foquest's duration profile. Some patients may experience symptom return in late afternoon/evening and require supplemental immediate-release methylphenidate 2.
Abuse potential: Concerta has high abuse potential; assess risk factors before prescribing and monitor for signs of misuse 1. The OROS formulation is resistant to tampering (cannot be crushed or snorted), making it preferable for patients at higher diversion risk 8.
If improvement is not observed after appropriate dose adjustment over one month, consider discontinuing Concerta and evaluating alternative treatments 1.